Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective?

Authors

  • Rahil Alsadat Shahtaheri,

    1. Department of Health Economics, School of Health care Management, Shiraz University of Medical Sciences, Shiraz, Iran
    Search for more papers by this author
  • Afshin Borhani Haghighi,

    Corresponding author
    1. Research Center for Transgenic Technology and Stem cell, Shiraz University of Medical Sciences, Shiraz, Iran
    2. Departments of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran
    • Department of Health Economics, School of Health care Management, Shiraz University of Medical Sciences, Shiraz, Iran
    Search for more papers by this author
  • Anahid Safari,

    1. Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
    Search for more papers by this author
  • Salvador Cruz-Flores

    1. Department of Neurology, Saint Louis University, Saint Louis, MO, USA
    Search for more papers by this author

  • Conflict of interest: None declared.

Correspondence: Afshin Borhani Haghighi, Department of Neurology, Namazi Hospital, Shiraz 71847, Iran.

E-mail: borhanihaghighi@yahoo.com

No abstract is available for this article.

Ancillary